Area of research
Genetics · Hematology
Research interest
Research interests include Hemoglobinopathies and Related Disorders, Iron Metabolism and Disorders, Blood groups and transfusion, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Successes and pitfalls in orphan drug development for sickle cell disease
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
Genome‐wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates <i>ADAMTS2</i> and <i>CDK18</i> and uncovers novel loci
Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease
Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children
Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia
Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study
Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to non‐transfused cohorts
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia
Original Research: Sickle cell anemia and pediatric strokes: Computational fluid dynamics analysis in the middle cerebral artery
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members
Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease
Evidence gaps in the management of sickle cell disease: A summary of needed research
Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia
Management of Sickle Cell Disease
Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease
A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola
Pain and other non‐neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: Results from the SWiTCH clinical trial
Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia
Impact of hydroxyurea on clinical events in the BABY HUG trial
Effect of hydroxyurea treatment on renal function parameters: Results from the multi‐center placebo‐controlled BABY HUG clinical trial for infants with sickle cell anemia
Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia